Michael E. Mitchell
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Michael E. Mitchell has a total of 154 co-authors. Here are the top co-authors by number of shared publications:
James S. Tweddell
Division of Cardiothoracic Surgery, Cincinnati Children's Hospital, Cincinnati, Ohio
6 shared publications- Steven D. Zangwill
Division of Cardiology Phoenix Children's Hospital Phoenix Arizona USA
5 shared publications Aoy Tomita-Mitchell
Herma Heart Center, Children's Wisconsin, and Medical College of Wisconsin, Milwaukee, WI
4 shared publicationsMahua Dasgupta
Department of Pediatrics Medical College of Wisconsin Milwaukee Wisconsin USA
4 shared publicationsPippa M. Simpson
Department of Pediatrics Medical College of Wisconsin Milwaukee Wisconsin USA
4 shared publicationsSteven J. Kindel
Division of Pediatric Cardiology Department of Pediatrics Medical College of Wisconsin Herma Heart Institute Children's Wisconsin Milwaukee Wisconsin USA
4 shared publications
Latest Publications
- 4 March 2026
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
- Vol. 29, 78-84
Bilateral Bronchus Suis Tracheoplasty
- 4 March 2026
- Published by Elsevier in Seminars in Thoracic and Cardiovascular Surgery: Pediatric Cardiac Surgery Annual
- Vol. 29, 78-84
Bilateral Bronchus Suis Tracheoplasty
- 1 November 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (2) , 349-356
Nuclear Cell-Free DNA Predicts Adverse Events After Pediatric Cardiothoracic Surgery
- 1 November 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 116 (2) , 349-356
Nuclear Cell-Free DNA Predicts Adverse Events After Pediatric Cardiothoracic Surgery
- Open Access
- 3 October 2022
- Published by Springer Nature in Current Cardiology Reports
- Vol. 24 (10) , 1495-1503
Rings and Slings: Not Such Simple Things
Purpose of Review: Vascular rings are congenital malformations resulting from abnormal development of the great vessels, with the consequent encircling and compression of the trachea, esophagus, or both. We conducted a review of the current literature to identify the different management strategies that can be implemented based on the prognosis of each of these anomalies. Recent Findings: Although most vascular rings occur in isolation, they can also be associated with other congenital cardiac and/or respiratory diseases; therefore, thorough investigation is necessary before definitive surgical repair. Clinical presentation varies from asymptomatic to severe, with both respiratory and digestive symptoms. Although early surgical results are acceptable, the long-term outcome is variable; therefore, there is still controversy regarding the appropriate timing of treatment. This is especially true with regard to the Kommerell diverticulum (KD) and in patients without symptoms at the time of initial surgical evaluation. Summary: As more sophisticated diagnostic tools have become available and more studies on adults affected by this condition have been published, understanding of this condition and its additional clinical implications has grown and appears to be tilting management toward earlier intervention.
- 3 October 2022
- Published by Springer Nature in Current Cardiology Reports
- Vol. 24 (10) , 1495-1503
Open AccessRings and Slings: Not Such Simple Things
Purpose of Review: Vascular rings are congenital malformations resulting from abnormal development of the great vessels, with the consequent encircling and compression of the trachea, esophagus, or both. We conducted a review of the current literature to identify the different management strategies that can be implemented based on the prognosis of each of these anomalies. Recent Findings: Although most vascular rings occur in isolation, they can also be associated with other congenital cardiac and/or respiratory diseases; therefore, thorough investigation is necessary before definitive surgical repair. Clinical presentation varies from asymptomatic to severe, with both respiratory and digestive symptoms. Although early surgical results are acceptable, the long-term outcome is variable; therefore, there is still controversy regarding the appropriate timing of treatment. This is especially true with regard to the Kommerell diverticulum (KD) and in patients without symptoms at the time of initial surgical evaluation. Summary: As more sophisticated diagnostic tools have become available and more studies on adults affected by this condition have been published, understanding of this condition and its additional clinical implications has grown and appears to be tilting management toward earlier intervention.
- 9 July 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 115 (2) , 453-460
The Supported vs Unsupported Ross in Pediatric Patients: Neoaortic Root and Ventricular Function
- 9 July 2022
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 115 (2) , 453-460
The Supported vs Unsupported Ross in Pediatric Patients: Neoaortic Root and Ventricular Function
- Open Access
- 3 May 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (5) , 144
Significance of α-Myosin Heavy Chain (MYH6) Variants in Hypoplastic Left Heart Syndrome and Related Cardiovascular Diseases
Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with complex genetic inheritance. HLHS segregates with other left ventricular outflow tract (LVOT) malformations in families, and can present as either an isolated phenotype or as a feature of a larger genetic disorder. The multifactorial etiology of HLHS makes it difficult to interpret the clinical significance of genetic variants. Specific genes have been implicated in HLHS, including rare, predicted damaging MYH6 variants that are present in >10% of HLHS patients, and which have been shown to be associated with decreased transplant-free survival in our previous studies. MYH6 (α-myosin heavy chain, α-MHC) variants have been reported in HLHS and numerous other CHDs, including LVOT malformations, and may provide a genetic link to these disorders. In this paper, we outline the MYH6 variants that have been identified, discuss how bioinformatic and functional studies can inform clinical decision making, and highlight the importance of genetic testing in HLHS.
- 3 May 2022
- Published by MDPI AG in Journal of Cardiovascular Development and Disease
- Vol. 9 (5) , 144
Open AccessSignificance of α-Myosin Heavy Chain (MYH6) Variants in Hypoplastic Left Heart Syndrome and Related Cardiovascular Diseases
Hypoplastic left heart syndrome (HLHS) is a severe congenital heart disease (CHD) with complex genetic inheritance. HLHS segregates with other left ventricular outflow tract (LVOT) malformations in families, and can present as either an isolated phenotype or as a feature of a larger genetic disorder. The multifactorial etiology of HLHS makes it difficult to interpret the clinical significance of genetic variants. Specific genes have been implicated in HLHS, including rare, predicted damaging MYH6 variants that are present in >10% of HLHS patients, and which have been shown to be associated with decreased transplant-free survival in our previous studies. MYH6 (α-myosin heavy chain, α-MHC) variants have been reported in HLHS and numerous other CHDs, including LVOT malformations, and may provide a genetic link to these disorders. In this paper, we outline the MYH6 variants that have been identified, discuss how bioinformatic and functional studies can inform clinical decision making, and highlight the importance of genetic testing in HLHS.
- 14 October 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (1) , e14509
Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients
Background: Cell‐free DNA is an emerging biomarker. While donor fraction may detect graft events in heart transplant recipients, the prognostic value of total nuclear cell‐free DNA (ncfDNA) itself is largely unexplored.Objective: Explore the relationship between ncfDNA and clinical events in heart transplant recipients.Methods: We conducted a multi‐center prospective study to investigate the value of cell‐free DNA in non‐invasive monitoring following heart transplantation. Over 4000 blood samples were collected from 388 heart transplant patients. Total ncfDNA and donor fraction were quantified. Generalized linear models with maximum likelihood estimation for repeated measures with subjects as clusters were used to explore the relationship of ncfDNA and major adverse events. Receiver operating characteristic curves were used to help choose cutpoints.Results: A ncfDNA threshold (50 ng/ml) was identified that was associated with increased risk of major adverse events. NcfDNA was elevated in patients who suffered cardiac arrest, required mechanical circulatory support or died post heart transplantation as well as in patients undergoing treatment for infection.Conclusions: Elevated ncfDNA correlates with risk for major adverse events in adult and pediatric heart transplant recipients and may indicate a need for enhanced surveillance after transplant.
- 14 October 2021
- Published by Wiley in Clinical Transplantation
- Vol. 36 (1) , e14509
Increase in nuclear cell‐free DNA is associated with major adverse events in adult and pediatric heart transplant recipients
Background: Cell‐free DNA is an emerging biomarker. While donor fraction may detect graft events in heart transplant recipients, the prognostic value of total nuclear cell‐free DNA (ncfDNA) itself is largely unexplored.Objective: Explore the relationship between ncfDNA and clinical events in heart transplant recipients.Methods: We conducted a multi‐center prospective study to investigate the value of cell‐free DNA in non‐invasive monitoring following heart transplantation. Over 4000 blood samples were collected from 388 heart transplant patients. Total ncfDNA and donor fraction were quantified. Generalized linear models with maximum likelihood estimation for repeated measures with subjects as clusters were used to explore the relationship of ncfDNA and major adverse events. Receiver operating characteristic curves were used to help choose cutpoints.Results: A ncfDNA threshold (50 ng/ml) was identified that was associated with increased risk of major adverse events. NcfDNA was elevated in patients who suffered cardiac arrest, required mechanical circulatory support or died post heart transplantation as well as in patients undergoing treatment for infection.Conclusions: Elevated ncfDNA correlates with risk for major adverse events in adult and pediatric heart transplant recipients and may indicate a need for enhanced surveillance after transplant.
- 1 October 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 112 (4) , 1282-1289
Total Cell-Free DNA Predicts Death and Infection Following Pediatric and Adult Heart Transplantation
- 1 October 2021
- Published by Elsevier in The Annals of Thoracic Surgery
- Vol. 112 (4) , 1282-1289
Total Cell-Free DNA Predicts Death and Infection Following Pediatric and Adult Heart Transplantation
- 1 September 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (3) , 807-808
Commentary: A long haul and a short slide?
- 1 September 2020
- Published by Elsevier in The Journal of Thoracic and Cardiovascular Surgery
- Vol. 160 (3) , 807-808
Commentary: A long haul and a short slide?
- 1 August 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (1) , 22-28
Nitric oxide added to the sweep gas of the oxygenator during cardiopulmonary bypass in infants: A pilot randomized controlled trial
Our objective was to assess the effect of nitric oxide added to the sweep gas of the oxygenator during cardiopulmonary bypass (CPB) in infants on platelet count, platelet function, clinical outcomes, and safety. A randomized, double‐blinded, placebo‐controlled clinical trial in infants less than a year of age undergoing cardiac surgery requiring CPB was undertaken. Nitric oxide at a dose of 20 ppm was added to the sweep gas in the treatment group. Blood was collected at baseline and prior to separation from CPB to measure platelet count and function as determined by responsiveness to specific agonists. Clinical outcomes were observed through hospital discharge. Methemoglobin levels were measured preoperatively, at the conclusion of CPB, and upon admission to the ICU. Forty patients consented and were randomized in the trial. Eighteen patients were randomized to the treatment group and 22 were included in the placebo group. The groups were similar in terms of age, weight, gender, and surgical complexity. No significant differences were found in measures of platelet count, platelet response to agonist, or clinical outcomes. Patients in the treatment group had higher methemoglobin levels after receiving nitric oxide, but no levels approached toxicity (maximum 2.4%). Nitric oxide added to the sweep gas of the oxygenator during CPB in infants did not have an appreciable effect on the preservation of platelet count, platelet responsiveness to agonist, or clinical outcomes. Methemoglobin levels were increased after receiving nitric oxide but were far below a toxic level of 15%.
- 1 August 2020
- Published by Wiley in Artificial Organs
- Vol. 45 (1) , 22-28
Nitric oxide added to the sweep gas of the oxygenator during cardiopulmonary bypass in infants: A pilot randomized controlled trial
Our objective was to assess the effect of nitric oxide added to the sweep gas of the oxygenator during cardiopulmonary bypass (CPB) in infants on platelet count, platelet function, clinical outcomes, and safety. A randomized, double‐blinded, placebo‐controlled clinical trial in infants less than a year of age undergoing cardiac surgery requiring CPB was undertaken. Nitric oxide at a dose of 20 ppm was added to the sweep gas in the treatment group. Blood was collected at baseline and prior to separation from CPB to measure platelet count and function as determined by responsiveness to specific agonists. Clinical outcomes were observed through hospital discharge. Methemoglobin levels were measured preoperatively, at the conclusion of CPB, and upon admission to the ICU. Forty patients consented and were randomized in the trial. Eighteen patients were randomized to the treatment group and 22 were included in the placebo group. The groups were similar in terms of age, weight, gender, and surgical complexity. No significant differences were found in measures of platelet count, platelet response to agonist, or clinical outcomes. Patients in the treatment group had higher methemoglobin levels after receiving nitric oxide, but no levels approached toxicity (maximum 2.4%). Nitric oxide added to the sweep gas of the oxygenator during CPB in infants did not have an appreciable effect on the preservation of platelet count, platelet responsiveness to agonist, or clinical outcomes. Methemoglobin levels were increased after receiving nitric oxide but were far below a toxic level of 15%.
- Open Access
- 1 May 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (5) , 454-463
Donor fraction cell-free DNA and rejection in adult and pediatric heart transplantation
- 1 May 2020
- Published by Elsevier in The Journal of Heart and Lung Transplantation
- Vol. 39 (5) , 454-463
Open AccessDonor fraction cell-free DNA and rejection in adult and pediatric heart transplantation